Abstract | BACKGROUND: METHODS: RESULTS: Of 114 subjects, 109 received empiric vancomycin therapy in combination with cefotaxime or ceftriaxone. Ten subjects (9%) died, whereas 37 (55%) of 67 survivors who underwent audiometry had documented hearing loss, and 14 (13%) of 104 survivors were discharged with other neurologic deficits. Subjects with hearing loss had a significantly shorter median vancomycin start time than did those with normal hearing (<1 vs 4 hours). Vancomycin start time was not significantly associated with death or other neurologic deficits in univariate or multivariate analyses. Multiple logistic regression revealed that hearing loss was independently associated with vancomycin start time <2 hours, blood leukocyte count <15000/microL, and cerebrospinal fluid glucose concentration <30 mg/dL. CONCLUSIONS:
|
Authors | Steven C Buckingham, Jonathan A McCullers, Jorge Luján-Zilbermann, Katherine M Knapp, Karen L Orman, B Keith English |
Journal | Pediatrics
(Pediatrics)
Vol. 117
Issue 5
Pg. 1688-94
(May 2006)
ISSN: 1098-4275 [Electronic] United States |
PMID | 16651325
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Vancomycin
- Ceftriaxone
- Cefotaxime
|
Topics |
- Anti-Bacterial Agents
(administration & dosage)
- Cefotaxime
(administration & dosage)
- Ceftriaxone
(administration & dosage)
- Drug Therapy, Combination
- Female
- Hearing Loss, Sensorineural
(etiology, prevention & control)
- Humans
- Infant
- Male
- Meningitis, Pneumococcal
(complications, drug therapy, mortality)
- Survival Rate
- Vancomycin
(administration & dosage)
|